BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20730520)

  • 1. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
    Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
    Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
    Glinicki P; Kapuścińska R; Jeske W
    Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
    Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
    Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of three commercially available ELISA kits for the determination of chromogranin A.
    Eeckhout K; Van Cotthem K; Guerti K
    J Immunoassay Immunochem; 2021 Mar; 42(2):95-105. PubMed ID: 33043835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 6. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
    Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
    Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
    Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
    Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
    Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specific enolase in patients with lung cancer.
    Body JJ; Paesmans M; Sculier JP; Dabouis G; Bureau G; Libert P; Berchier MC; Raymakers N; Klastersky J
    Clin Chem; 1992 May; 38(5):748-51. PubMed ID: 1316245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
    Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between three commercial kits for chromogranin A measurements.
    Stridsberg M; Eriksson B; Oberg K; Janson ET
    J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
    Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
    Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
    Giovanella L; Ceriani L; Bandera M; Garancini S
    Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
    Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
    Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of three chromogranin A assays in patients with neuroendocrine tumours.
    Brehm Hoej L; Parkner T; Soendersoe Knudsen C; Grønbaek H
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):419-24. PubMed ID: 25532001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.